Dutch Life Sciences Trend Analysis: Record year of venture financing
Biotechgate, the leading global biotech database, presents the annual Trend Analysis Report for the Dutch life sciences sector. The report shows a stable amount of life sciences companies and a sector which has grown in maturity. Biotech companies were successful in attracting venture capital; 2019 is a record year for venture financing.
Dutch biotech companies have shown to be successful in attracting new venture financing to their businesses. $293.65 million was raised in twelve private equity rounds. The biggest financing round, $130 million was raised by AM-Pharma.
Biotechgate currently lists 678 R&D life sciences companies in the Netherlands, 87% of the companies are small to medium sized enterprises (SMEs). Oncology remains the most prominent therapeutic area, followed by neurology and infectious diseases. With many ground-breaking companies and world-class universities, the Netherlands is the perfect location for biopharmaceutical innovation in Europe.
HollandBIO’s managing director Annemiek Verkamman is proud of the Dutch life sciences sector. “The life sciences sector is growing and getting more mature. Venture capitalists are getting more familiar with the specific business model of biotech companies and biotech companies are gaining experience in fund raising. This results in a record year for funding. By combining outstanding research, education and entrepreneurial spirit this sector trend can be successfully continued.”
Whether you are looking to partner with a Dutch company or looking for a specific service, you’ll find the most complete overview of the Dutch life sciences sector at www.dutchbiotech.com.